DESTINY-LUNG01

NCT03505710 📎

Regimen

Experimental
T-DXd 6.4 mg/kg
Control
none

Population

HER2-mut pre-treated NSCLC

Key finding

ORR 55% (44-65); mDOR 9.3 mo; mPFS 8.2 mo; first HER2-targeted ADC efficacy in NSCLC

Source: PMID 34534430

Timeline

  • Enrollment start: 2018-05-21 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.113)
  • CSCO NSCLC 2025 ⚠️ OCR source